Antidepressant medication use and nasopharyngeal cancer risk: a nationwide population-based study
Received 29 December 2017
Accepted for publication 13 March 2018
Published 30 April 2018 Volume 2018:14 Pages 1101—1106
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Wai Kwong Tang
Chiao-Fan Lin,1,2,* Hsiang-Lin Chan,1,2 Yi-Hsuan Hsieh,1,2 Hsin-Yi Liang,1,2 Wei-Che Chiu,3,4,* Yena Lee,5 Roger S McIntyre,5,6 Vincent Chin-Hung Chen2,7,8
1Department of Child Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; 2Department of Psychiatry, Chang Gung University, Taoyuan, Taiwan; 3Department of Psychiatry, Cathay General Hospital, Taipei, Taiwan; 4School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan; 5Mood Disorders Psychopharmacology Unit, Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; 6Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; 7Medical Research Department, Health Information and Epidemiology Laboratory, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; 8Department of Psychiatry, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
*These authors contributed equally to this work
Background: The association between antidepressant exposure and nasopharyngeal cancer (NPC) has not been previously explored. The purpose of this study was to investigate the association between antidepressant prescription, including novel antidepressants, and the risk of NPC in a population-based study.
Materials and methods: Data for the analysis were derived from National Health Insurance Research Database. We identified 16,957 cases with a diagnosis of NPC and 83,231 matched controls by using a nested case–control design. A conditional logistic regression model was used, with adjustments for potentially confounding variables (eg, comorbid physical diseases, comorbid psychiatric diseases, and other medications).
Results: We report no association between NPC incidence and antidepressant prescription. For all classes of antidepressants, antidepressant exposure, regardless of cumulative dose, had no significant effect on NPC incidence (adjusted odds ratio of cumulative selective serotonin reuptake inhibitor exposure ≥336 defined daily dose was 1.18 [95% CI: 0.90–1.53]; tricyclic antidepressant exposure ≥336 defined daily dose was 1.18 [95% CI: 0.80–1.74]).
Conclusion: There was no association between antidepressant prescription and incident NPC.
Keywords: nasopharyngeal cancer, antidepressants, Taiwan national insurance
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]